Sleep Disorder Management

Adverse Effects of Zolpidem

Zolpidem use is associated with significant risks of adverse effects, including fractures (adjusted odds ratio 1.72) and major head injuries requiring hospitalization (adjusted hazard ratio 1.67), particularly in elderly patients 1
The risk of falls and fractures is increased in elderly patients, with an adjusted odds ratio of 1.72 for fractures 1
Zolpidem is also associated with a higher incidence of memory impairment compared to placebo 1
Complex sleep behaviors, including sleep-driving, making and eating food, talking on the phone, having sex, and sleepwalking, can occur with zolpidem use, leading to serious injury or death, as reported by the American Academy of Sleep Medicine and American College of Physicians 1
Common adverse effects of zolpidem include dizziness, headache, drowsiness, nausea, and taste perversion (altered or unpleasant taste), according to the American Academy of Sleep Medicine 2

The American Academy of Sleep Medicine recommends using zolpidem for short-term treatment periods (≤4 weeks) 3
Intermittent dosing, or "as-needed" zolpidem, may be safer than daily use for long periods 1
The recommended dose for elderly patients (≥65 years) is 5mg immediate-release or 6.25mg extended-release for zolpidem, due to slower drug clearance, as recommended by the American Academy of Sleep Medicine 2
The recommended dosing for women is 5 mg immediate-release and 6.25 mg extended-release for zolpidem, compared to 10 mg immediate-release and 12.5 mg extended-release for men, due to slower drug clearance in women, as recommended by the FDA and American Medical Association 4, 5

Zolpidem reduces time to fall asleep by 11-19 minutes, increases total sleep time by approximately 28-30 minutes, shows moderate to large improvements in sleep quality, demonstrates clinically significant improvement in sleep efficiency, and shows clinically significant reduction in wake after sleep onset (WASO) 2
Immediate-release tablets (Ambien) reduce sleep latency by 11-19 minutes compared to placebo, primarily for sleep onset difficulties, according to the American Academy of Sleep Medicine 2 and the Annals of Internal Medicine 1
Extended-release formulation (Ambien CR) improves sleep maintenance in the first 6 hours of sleep, and 85% of patients report being "much or very much improved" versus 48% with placebo, as reported by the American Academy of Sleep Medicine 2 and the Annals of Internal Medicine 1
Sublingual formulations (Edluar, Intermezzo) reduce sleep onset latency after awakening by approximately 18 minutes, for middle-of-the-night awakenings with difficulty returning to sleep, according to the Annals of Internal Medicine 1

The American College of Physicians recommends considering cognitive behavioral therapy for insomnia (CBT-I) as the first-line treatment 3
Treating underlying causes of insomnia, such as alleviating or treating the causative condition (e.g., pain) or removing the causative agent (e.g., medication), is recommended when possible 3
The American Academy of Sleep Medicine recommends suvorexant (Belsomra) 15 mg for elderly patients with insomnia due to its significantly lower risks of cognitive impairment, falls, and complex sleep behaviors compared to zolpidem 1
Suvorexant reduces sleep latency by 11-19 minutes compared to placebo and increases total sleep time by approximately 23-28 minutes 2, 1
The primary adverse effect of suvorexant is somnolence (7% vs 3% for placebo) 1

Elderly patients should be monitored for next-day drowsiness and cognitive function, risk of falls, sleep quality improvement, and development of tolerance or dependence 1
The American Academy of Sleep Medicine suggests that zolpidem should be used with extreme caution in elderly patients, ensuring 7-8 hours of sleep opportunity, and monitoring closely for adverse effects 1
Concomitant use of SSRIs or other CNS depressants should be avoided, and zolpidem should not be taken with alcohol or other sedatives unless directed by a healthcare provider, as suggested by the American College of Physicians 1
Ensuring patients have a full 7-8 hours available for sleep after taking zolpidem and warning them about potential next-day impairment affecting driving and activities requiring alertness are important considerations, as noted by the American Academy of Sleep Medicine and FDA 4, 2
Stopping zolpidem can lead to rebound insomnia, trouble sleeping, nausea, flushing, lightheadedness, uncontrolled crying, vomiting, stomach cramps, panic attacks, and nervousness, with rare reports of seizures, particularly with high doses, as reported by the American College of Physicians 1